Poxel SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0012432516
EUR
0.24
-6.08 (-96.27%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

78.26 k

Shareholding (Dec 2022)

FII

1.30%

Held by 1 FIIs

DII

98.7%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 13 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.96

stock-summary
Return on Equity

22.46%

stock-summary
Price to Book

-0.21

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-96.41%
0%
-96.41%
6 Months
-96.96%
0%
-96.96%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Poxel SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
-4.73%
EBIT Growth (5y)
14.27%
EBIT to Interest (avg)
-11.51
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.90
Sales to Capital Employed (avg)
-0.82
Tax Ratio
1.90%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
1.30%
ROCE (avg)
0
ROE (avg)
0.19%

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.22
EV to EBIT
-39.94
EV to EBITDA
-40.63
EV to Capital Employed
-29.26
EV to Sales
9.45
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2022stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (1.3%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Poxel SA"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 230.00% vs 185.71% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 47.86% vs -11.78% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6.60",
          "val2": "2.00",
          "chgp": "230.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.50",
          "val2": "-12.00",
          "chgp": "70.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "14.00",
          "val2": "6.10",
          "chgp": "129.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.30",
          "val2": "0.20",
          "chgp": "50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-18.30",
          "val2": "-35.10",
          "chgp": "47.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-551.80%",
          "val2": "-14,801.60%",
          "chgp": "1,424.98%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
6.60
2.00
230.00%
Operating Profit (PBDIT) excl Other Income
-3.50
-12.00
70.83%
Interest
14.00
6.10
129.51%
Exceptional Items
0.30
0.20
50.00%
Consolidate Net Profit
-18.30
-35.10
47.86%
Operating Profit Margin (Excl OI)
-551.80%
-14,801.60%
1,424.98%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 230.00% vs 185.71% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 47.86% vs -11.78% in Dec 2023

stock-summaryCompany CV
About Poxel SA stock-summary
stock-summary
Poxel SA
Pharmaceuticals & Biotechnology
Poxel SAS is a France-based company principally engaged in the biopharmaceutical sector. The Company develops drugs with a focus on Type 2 diabetes. The Company aims at developing drugs from preclinical to phase 2 clinical proof of concept. Its lead product, Imeglimin, is in clinical phase 2 study for Type 2 diabetes indication. A direct activator of AMPK for the treatment of Type 2 diabetes has started its preclinical development, and other projects in the research phase target diabetes and other metabolic diseases with small molecules that have a disease-modifying mechanism of action. Poxel SAS was spun out from Merck Serono. The Company cooperates with the Laboratory for Fundamental and Applied Bioenergetics, Sumitomo Dainippon Pharma, Joseph Fourier University and Department of Cell Physiology and Metabolism at the University of Geneva, Switzerland, among others.
Company Coordinates stock-summary
Company Details
Imm Le Sunway, 259/261 Avenue Jean Jaures LYON None : 69007
stock-summary
Tel: 33 4 373720101 617 8182985
stock-summary
Registrar Details